Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
6.24 USD -4.00% Intraday chart for Vanda Pharmaceuticals Inc. +1.96% +47.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Softer Thursday Afternoon MT
Sector Update: Health Care MT
Vanda Pharmaceuticals Receives Revised Offer From Future Pak; Shares Rise MT
Future Pak raises cash portion of buyout offer for Vanda RE
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care Stocks Advance Thursday Afternoon MT
Sector Update: Health Care MT
Vanda Pharmaceuticals' Shares Rally After Company Receives $466 Million Buyout Offer From Cycle Pharma MT
Cycle Pharmaceuticals Offers to Buy Vanda Pharmaceuticals for $466 Million MT
Top Premarket Gainers MT
Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. for approximately $490 million. CI
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US MT
Global markets live: UBS, Tesla, Nvidia, Apple, Micron... Our Logo
Vanda Pharmaceuticals rejects Future Pak's revised takeover offer RE
Vanda Pharmaceuticals rejects Future Pak's deal RE
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc., Butler Hall Capital LLC, Shareholder Capital LLC and others. CI
Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results MT
Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness CI
Transcript : Vanda Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M MT
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading MT
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT
Sector Update: Health Care MT
Chart Vanda Pharmaceuticals Inc.
More charts
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
6.24 USD
Average target price
5.21 USD
Spread / Average Target
-16.51%
Consensus
  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. News Vanda Pharmaceuticals Inc.
  5. Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW